NCT00565851
Clinical Trial Information
Trial Number: NCT00565851 (ClinicalTrials.gov)
Disease Type:
- Reproductive System Neoplasm, Female - Ovarian Cancer (excluding Ovarian Germ Cell Cancer)
Trial Title:
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Study ID:
GOG-0213
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00565851-D2 | This dataset contains quality of life (QOL) data from trial NCT00565851 presented in PMID - 31722153. |
| NCT00565851-D1 | This dataset contains the treatment comparison data for secondary cytoreduction before chemotherapy and chemotherapy alone in trial NCT00565851. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®